South America Ovarian Cancer Diagnostics And Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Ovarian Cancer Diagnostics And Therapeutics Market Trends and Insights

Increasing Incidences of Ovarian Cancer

In Andean nations, age-standardized incidence rates of ovarian cancer are rising at an annual rate between 2.1% and 2.7%, surpassing the global average. In 2022, Brazil reported 7,710 new ovarian cancer diagnoses and anticipates a 9% yearly increase through 2030.^{[2]World Health Organization, “Cancer Fact Sheet,” who.int} This projection is driven by the continued adoption of opportunistic rather than systematic screening approaches. Over 60% of diagnosed cases remain at FIGO stages III or IV, limiting overall survival to 32 months. This late-stage diagnosis has significantly increased the demand for platinum-based chemotherapy and first-line PARP inhibitor maintenance treatments. To address this, health ministries are piloting risk-stratified screening programs. For instance, Chile’s hereditary registry now connects BRCA carriers directly to prophylactic surgeries.^{[3]Chilean Ministry of Health, “Programa Nacional de Cáncer,” minsal.cl} Pharmaceutical companies are prioritizing the region for drug launches, as evidenced by the eight-month approval lead for olaparib in Brazil compared to the United States. 

Rising Geriatric Female Population

By 2035, the percentage of South American women aged 65 and older is projected to rise from 8.1% in 2025 to 11.3%. Since the risk of ovarian cancer peaks between ages 55 and 74, this growing elderly demographic is expected to increase both the number of incident cases and the duration of maintenance therapy. In response, tertiary centers are establishing geriatric oncology units to address challenges like polypharmacy and frailty, favoring oral targeted agents and outpatient infusions over traditional inpatient chemotherapy. With longer life expectancies, there is also a rise in surveillance testing. Serial CA-125 assays and liquid biopsies are now reimbursed, enabling earlier detection of biochemical recurrences before they progress to imaging. 

Growing Healthcare Expenditure & Insurance Coverage

In 2024, Brazil allocated approximately USD 28 billion to healthcare, with over half directed toward hospital and outpatient services. Additionally, Brazil expanded its essential medicines list by incorporating 14 new oncology drugs. Peru invested USD 120 million to upgrade 22 regional oncology centers, successfully reducing the median time-to-treatment from 47 days in 2023 to a targeted 29 days in 2025. In Chile, the national health fund now covers 78% of the population and recently included bevacizumab-paclitaxel in its guaranteed benefits package, resulting in an 81% reduction in average first-line out-of-pocket expenses. These initiatives are streamlining patient access to evidence-based treatment pathways.

Rapid Uptake of PARP Inhibitors & Other Targeted Therapies

Following promising results from the OCEANIA registry, which involved 1,240 patients, both olaparib and niraparib have made significant inroads into maintenance therapy across Brazil, Argentina, and Chile. This figure aligns with the nation's willingness-to-pay benchmark. Meanwhile, mirvetuximab soravtansine, an antibody-drug conjugate targeting folate receptor alpha, received approval in 2024 and is currently under review by regulatory authorities. Early-access data showcase a promising 32% objective response rate in patients with platinum-resistant conditions. 

Low Awareness Leading to Late-Stage Diagnosis

In rural Peru and Colombia, symptom-awareness campaigns reach fewer than 35% of women. This limited reach results in a median diagnostic delay of 7.2 months, more than double that observed in metropolitan São Paulo and Buenos Aires. Patients diagnosed at Stage IV are often ineligible for cytoreductive surgery and face treatment costs that are 2.8 times higher, primarily due to extended chemotherapy and palliative care. While Chile’s pilot program utilizing community health workers shows potential, the issue of sustainable funding remains unresolved.

High Cost of Targeted Drugs & Companion Diagnostics

In Argentina, Olaparib is priced at ARS 1.2 million (USD 3,400) per month. This cost, which is four times the median household income, leads 38% of patients to discontinue therapy within six months. Germline BRCA testing, available in private labs, costs between USD 800 and 1,200. However, the reimbursement authorization process can take 90 to 120 days, delaying precision medicine decisions. In Peru, EsSalud has set an annual cap of USD 30,000 on PARP spending. This threshold is exceeded by two-thirds of recipients, forcing them to switch to generic chemotherapy or rely on manufacturer assistance programs. Advocacy groups are advocating for performance-based contracts that ensure reimbursement only when a biomarker-defined response is documented, following the example of Chile’s 2024 pembrolizumab model.

Segment Analysis

By Cancer Type: Epithelial Tumors Widen Their Lead

Epithelial tumors accounted for 68.67% of South America's ovarian cancer diagnostics and therapeutics market revenue in 2025, with an anticipated growth rate of 11.5% CAGR through 2031. High-grade serous carcinoma, representing over half of all epithelial diagnoses, demonstrates the highest prevalence of BRCA and HRD, driving the adoption of PARP inhibitors. Local trials for PI3K and AKT inhibitors are gaining momentum, particularly for clear-cell and endometrioid variants, with alpelisib currently in a phase II study in Brazil involving 180 patients. 

Ongoing molecular segmentation is expected to further refine treatment algorithms. The increasing adoption of comprehensive genomic profiling enables oncologists to identify actionable mutations such as PIK3CA, ARID1A, and PTEN, creating opportunities for targeted therapy combinations. Advocacy groups are actively promoting subtype-specific clinical-trial enrollment criteria to accelerate access to experimental treatments. 

Note: Segment shares of all individual segments available upon report purchase

By Diagnostic Modality: Liquid Biopsy Accelerates Genomic Insight

Blood-based CA-125 assays remain a cornerstone of diagnostic workflows, contributing 34.45% of 2025's revenue. However, their dominance is diminishing as liquid-biopsy assays gain traction, growing at a 12.80% CAGR following the approval of Guardant360 CDx, the first comprehensive ctDNA test for ovarian cancer. The market for liquid-biopsy platforms in South America is projected to approach USD 950 million by 2031, driven by their ability to detect resistance mutations without the need for invasive tissue re-biopsies. 

Laboratory networks are consolidating to scale next-generation sequencing capabilities, with major players deploying advanced systems in key locations such as São Paulo and Buenos Aires. Additionally, payers are increasingly bundling reimbursements for molecular testing with companion therapeutics, facilitating broader adoption. 

By Therapeutic Modality: Targeted Agents Redefine Maintenance

In 2025, chemotherapy retained a 42.27% revenue share, primarily supported by cost-effective carboplatin-paclitaxel doublets supplied by regional generics. However, targeted therapies are experiencing the fastest growth, with a 14.64% CAGR through 2031. Drugs such as olaparib, niraparib, and rucaparib are gaining significant traction in first-line maintenance for BRCA-mutated and HRD-positive patients. The market share of targeted agents is expected to exceed 35% by 2031, supported by the anticipated approval of mirvetuximab soravtansine in Brazil. 

Price reductions are becoming evident, with biosimilars of bevacizumab significantly lowering per-cycle costs by over 50% in 2024, thereby improving accessibility within Brazil’s public health system. Additionally, value-based contracts for PARP inhibitors, which offer refunds for non-responsive patients, are under active negotiation. 

Note: Segment shares of all individual segments available upon report purchase

By End User: Ambulatory Migration Gains Speed

Hospitals accounted for 62.09% of spending in 2025, driven by their role in cytoreductive surgeries and high-acuity chemotherapy infusions. However, ambulatory surgical centers are expanding rapidly, with an 11.85% CAGR, supported by minimally invasive laparoscopy and same-day discharge protocols that reduce per-case costs by 40% compared to inpatient care. Rede D’Or has opened seven oncology-focused ambulatory units between 2024 and 2025, targeting an 85% same-day discharge rate. 

Diagnostic laboratories are also consolidating, with key players merging select sequencing operations to enhance purchasing power for genomic reagents. This consolidation supports standardized reporting and faster turnaround times, which are critical for timely maintenance-therapy decisions. 

Geography Analysis

In 2025, Brazil accounted for 47.34% of South America's ovarian cancer diagnostics and therapeutics market revenue. This leadership was driven by its 108 million women of reproductive age and a universal public insurance system reimbursing over 75% of medical visits. Global pharmaceutical companies, including AstraZeneca and Roche, have established trial coordination hubs in São Paulo to leverage extensive patient pools and expedite enrollment processes.

Argentina held a 22% revenue share in 2025, supported by PAMI's coverage of 5.2 million retirees, the highest-risk demographic. Economic instability has led to the adoption of risk-sharing models, where manufacturers reimburse payers if predefined clinical outcomes are not achieved.

Peru is experiencing the fastest growth, with the market projected to expand at a 10.35% CAGR through 2031. EsSalud's insurance expansion now includes 1.8 million informal-sector workers, while significant investments in oncology centers have reduced treatment delays and improved early diagnosis rates. Chile's hereditary registry sets a benchmark for BRCA-carrier management, with Uruguay exploring a similar initiative. Bolivia and Ecuador, facing rising incidence rates, continue to rely on cross-border referrals to advanced centers in Brazil and Argentina.